# KANAPH Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kanaph-therapeutics

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.kanaphtx.com
- Total disclosed funding: $40M
- Latest round: Series C (Nov 12, 2024)
- Investors on record: 12

## About

Based in Seoul, South Korea, and founded in 2019, KANAPH Therapeutics Inc. focuses on developing innovative biotechnology solutions that target chronic diseases, enhancing treatment outcomes through advanced therapeutic applications. KANAPH Therapeutics Inc. is dedicated to advancing the biotechnology sector by developing targeted therapies. The founder's history is not publicly detailed, nor are any prior ventures indicated. The company has not been reported as a subsidiary or a result of a merger or carve-out. KANAPH Therapeutics Inc. specializes in developing innovative therapeutic solutions aimed at addressing significant health challenges. The company focuses on advancing research in biotechnology, particularly in developing targeted therapies that leverage proprietary technology platforms. Their core product offerings enhance the quality of life for patients suffering from chronic and complex diseases, specifically improving treatment outcomes in oncology and autoimmune disorders. KANAPH Therapeutics Inc.'s products are marketed to hospitals, clinics, and healthcare providers primarily in North America and Europe. KANAPH Therapeutics Inc. generates revenue through strategic partnerships and collaborations within the healthcare sector, particularly with pharmaceutical companies and research institutions. Business transactions typically occur through licensing agreements and joint ventures, allowing for the co-development of their therapeutic products. The company’s flagship offerings are integrated into clinical settings where they are distributed directly to healthcare professionals and institutions. Pricing models for these products are structured around value-based agreements, reflecting the efficacy and impact of their therapies on patient outcomes. KANAPH Therapeutics Inc. is focusing on launching new products that aim to address chronic diseases, although specific release dates have not been disclosed. The company is also planning to expand its presence in additional markets, specifically targeting new regions in North America and Europe by the end of 2025. In March 2026, KANAPH Therapeutics Inc. raised KRW 40 billion in an IPO, selling 2 million shares at KRW 20,000 apiece, within the KRW 16,000-20,000 per share range on the KOSDAQ.

## Funding rounds

- Series C, Nov 12, 2024, $2.5M — Premier Partners
- Series C, Dec 27, 2023, $18M — AJU IB Investment, InterVest, Solidus Investment, Premier Partners, Wooshin Venture Capital, GC Biopharma, DAYLI Partners, NH Venture Investment, LOTTE BIOLOGICS
- Series B, Oct 5, 2020, $20M — Korea Investment & Securities, Timefolio Asset Management, Kolon Investment, GC Biopharma

## Investors

- Korea Investment & Securities (https://capitalatlas.ai/funds/korea-investment-securities) — Series B
- Timefolio Asset Management — Series B
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series B
- GC Biopharma — Series B, Series C
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C
- InterVest (https://capitalatlas.ai/funds/intervest) — Series C
- Solidus Investment (https://capitalatlas.ai/funds/solidus-investment) — Series C
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series C
- Wooshin Venture Capital (https://capitalatlas.ai/funds/wooshin-venture-capital) — Series C
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series C
- NH Venture Investment (https://capitalatlas.ai/funds/nh-venture-investment) — Series C
- LOTTE BIOLOGICS — Series C